Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test
Diazyme Laboratories, Inc. announced today that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test. The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies1. Diazyme also announced plans to work with US FDA for EUA application.